These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

510 related articles for article (PubMed ID: 16010686)

  • 1. Dysferlin mutations in LGMD2B, Miyoshi myopathy, and atypical dysferlinopathies.
    Nguyen K; Bassez G; Bernard R; Krahn M; Labelle V; Figarella-Branger D; Pouget J; Hammouda el H; Béroud C; Urtizberea A; Eymard B; Leturcq F; Lévy N
    Hum Mutat; 2005 Aug; 26(2):165. PubMed ID: 16010686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of the DYSF mutational spectrum in a large cohort of patients.
    Krahn M; Béroud C; Labelle V; Nguyen K; Bernard R; Bassez G; Figarella-Branger D; Fernandez C; Bouvenot J; Richard I; Ollagnon-Roman E; Bevilacqua JA; Salvo E; Attarian S; Chapon F; Pellissier JF; Pouget J; Hammouda el H; Laforêt P; Urtizberea JA; Eymard B; Leturcq F; Lévy N
    Hum Mutat; 2009 Feb; 30(2):E345-75. PubMed ID: 18853459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel sequence variants in dysferlin-deficient muscular dystrophy leading to mRNA decay and possible C2-domain misfolding.
    Wenzel K; Carl M; Perrot A; Zabojszcza J; Assadi M; Ebeling M; Geier C; Robinson PN; Kress W; Osterziel KJ; Spuler S
    Hum Mutat; 2006 Jun; 27(6):599-600. PubMed ID: 16705711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of a novel founder mutation in the DYSF gene causing clinical variability in the Spanish population.
    Vilchez JJ; Gallano P; Gallardo E; Lasa A; Rojas-García R; Freixas A; De Luna N; Calafell F; Sevilla T; Mayordomo F; Baiget M; Illa I
    Arch Neurol; 2005 Aug; 62(8):1256-9. PubMed ID: 16087766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Painful enlargement of the calf muscles in limb girdle muscular dystrophy type 2B (LGMD2B) with a novel compound heterozygous mutation in DYSF.
    Diers A; Carl M; Stoltenburg-Didinger G; Vorgerd M; Spuler S
    Neuromuscul Disord; 2007 Feb; 17(2):157-62. PubMed ID: 17129727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dysferlin aggregation in limb-girdle muscular dystrophy type 2B/Miyoshi Myopathy necessitates mutational screen for diagnosis [corrected].
    Nilsson MI; Laureano ML; Saeed M; Tarnopolsky MA
    Muscle Nerve; 2013 May; 47(5):740-7. PubMed ID: 23519732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dysferlinopathy in the Jews of the Caucasus: a frequent mutation in the dysferlin gene.
    Leshinsky-Silver E; Argov Z; Rozenboim L; Cohen S; Tzofi Z; Cohen Y; Wirguin Y; Dabby R; Lev D; Sadeh M
    Neuromuscul Disord; 2007 Dec; 17(11-12):950-4. PubMed ID: 17825554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Private dysferlin exon skipping mutation (c.5492G>A) with a founder effect reveals further alternative splicing involving exons 49-51.
    Santos R; Oliveira J; Vieira E; Coelho T; Carneiro AL; Evangelista T; Dias C; Fortuna A; Geraldo A; Negrão L; Guimarães A; Bronze-da-Rocha E
    J Hum Genet; 2010 Aug; 55(8):546-9. PubMed ID: 20535123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dysferlin mutation analysis in a group of Italian patients with limb-girdle muscular dystrophy and Miyoshi myopathy.
    Kawabe K; Goto K; Nishino I; Angelini C; Hayashi YK
    Eur J Neurol; 2004 Oct; 11(10):657-61. PubMed ID: 15469449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel DYSF mutations in Thai patients with distal myopathy.
    Liewluck T; Pongpakdee S; Witoonpanich R; Sangruchi T; Pho-Iam T; Limwongse C; Thongnoppakhun W; Boonyapisit K; Sopassathit V; Phudhichareonrat S; Suthiponpaisan U; Raksadawan N; Goto K; Hayashi YK; Nishino I
    Clin Neurol Neurosurg; 2009 Sep; 111(7):613-8. PubMed ID: 19493611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Redefining dysferlinopathy phenotypes based on clinical findings and muscle imaging studies.
    Paradas C; Llauger J; Diaz-Manera J; Rojas-García R; De Luna N; Iturriaga C; Márquez C; Usón M; Hankiewicz K; Gallardo E; Illa I
    Neurology; 2010 Jul; 75(4):316-23. PubMed ID: 20574037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficient bypass of mutations in dysferlin deficient patient cells by antisense-induced exon skipping.
    Wein N; Avril A; Bartoli M; Beley C; Chaouch S; Laforêt P; Behin A; Butler-Browne G; Mouly V; Krahn M; Garcia L; Lévy N
    Hum Mutat; 2010 Feb; 31(2):136-42. PubMed ID: 19953532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phenotypic study in 40 patients with dysferlin gene mutations: high frequency of atypical phenotypes.
    Nguyen K; Bassez G; Krahn M; Bernard R; Laforêt P; Labelle V; Urtizberea JA; Figarella-Branger D; Romero N; Attarian S; Leturcq F; Pouget J; Lévy N; Eymard B
    Arch Neurol; 2007 Aug; 64(8):1176-82. PubMed ID: 17698709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutation finding in patients with dysferlin deficiency and role of the dysferlin interacting proteins annexin A1 and A2 in muscular dystrophies.
    Cagliani R; Magri F; Toscano A; Merlini L; Fortunato F; Lamperti C; Rodolico C; Prelle A; Sironi M; Aguennouz M; Ciscato P; Uncini A; Moggio M; Bresolin N; Comi GP
    Hum Mutat; 2005 Sep; 26(3):283. PubMed ID: 16100712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DYSF mutation analysis in a group of Chinese patients with dysferlinopathy.
    Zhao Z; Hu J; Sakiyama Y; Okamoto Y; Higuchi I; Li N; Shen H; Takashima H
    Clin Neurol Neurosurg; 2013 Aug; 115(8):1234-7. PubMed ID: 23254335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exclusion of mutations in the dysferlin alternative exons 1 of DYSF-v1, 5a, and 40a in a cohort of 26 patients.
    Krahn M; Labelle V; Borges A; Bartoli M; Lévy N
    Genet Test Mol Biomarkers; 2010 Feb; 14(1):153-4. PubMed ID: 19929428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Symptomatic dysferlin gene mutation carriers: characterization of two cases.
    Illa I; De Luna N; Domínguez-Perles R; Rojas-García R; Paradas C; Palmer J; Márquez C; Gallano P; Gallardo E
    Neurology; 2007 Apr; 68(16):1284-9. PubMed ID: 17287450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Variable reduction of caveolin-3 in patients with LGMD2B/MM.
    Walter MC; Braun C; Vorgerd M; Poppe M; Thirion C; Schmidt C; Schreiber H; Knirsch UI; Brummer D; Müller-Felber W; Pongratz D; Müller-Höcker J; Huebner A; Lochmüller H
    J Neurol; 2003 Dec; 250(12):1431-8. PubMed ID: 14673575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutation impact on dysferlin inferred from database analysis and computer-based structural predictions.
    Therrien C; Dodig D; Karpati G; Sinnreich M
    J Neurol Sci; 2006 Dec; 250(1-2):71-8. PubMed ID: 16996541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterisation of the dysferlin skeletal muscle promoter.
    Foxton RM; Laval SH; Bushby KM
    Eur J Hum Genet; 2004 Feb; 12(2):127-31. PubMed ID: 14560310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.